Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We recently showed that blocking Abs to mouse SIRPα enhanced both the Ab-dependent cellular phagocytosis (ADCP) activity of mouse macrophages for Burkitt's lymphoma Raji cells opsonized with an Ab to CD20 (rituximab) in vitro as well as the inhibitory effect of rituximab on the growth of tumors formed by Raji cells in nonobese diabetic (NOD)/SCID mice.
|
29473266 |
2018 |
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunocytochemistry analysis and a cell-based enzyme-linked immunosorbent assay using a Burkitt's lymphoma cell line showed that D4 mAbs are capable of binding to native extracellular epitopes of CD20.
|
27939822 |
2017 |
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data suggests that romidepsin is an active HDAC inhibitor that also potentiates expanded NK and anti-CD20 CAR exPBNK activity against rituximab-sensitive and -resistant BL.
|
28932644 |
2017 |
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We recently demonstrated that obinutuzumab (GA101), a novel glycoengineered type II CD20 Ab compared to rituximab (RTX) mediates significantly enhanced antibody-dependent cell cytotoxicity (ADCC) <i>in vitro</i> and increased overall survival in a Burkitt lymphoma (BL) xenograft non-obese diabetic severe combined immunodeficiency gamma (NSG) model.
|
29371955 |
2017 |
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Burkitt lymphoma (BL) is an aggressive B-cell neoplasm that is currently treated by intensive chemotherapy in combination with anti-CD20 antibodies.
|
28064214 |
2017 |
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Relatively few DHL cases showed dim expression of CD19 or CD20, and statistically significant differences were found only in the frequency of dim CD19 expression between DHL and BL or DLBCL.
|
23341189 |
2013 |
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The dynamic relationship between Gb(3)/CD77 and key B-cell membrane proteins was studied in Burkitt's lymphoma cells with a focus on CD20.
|
17336267 |
2007 |
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Statistically significant differences were found in the median levels of cyclin D1 mRNA (expressed as % CD20 mRNA) among cases of MCL (87.6), small lymphocytic lymphoma (9.9), follicular lymphoma (2.4), diffuse large B-cell lymphoma (5.9), marginal zone B-cell lymphoma (39.8), and Burkitt lymphoma (7.1) (P < 0.05).
|
12411587 |
2002 |
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BALM-13 was characterized as belonging to the Burkitt lymphoma group III cell type (CD10-, CD20+, CD23+, D39+, CD77-), and BALM-14 to the Burkitt lymphoma group I cell type (CD10+, CD20+, CD23-, CD39-, CD77+).
|
9183631 |
1996 |
Burkitt Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Burkitt's lymphomas were associated with EBV in 50% of cases, were monoclonal, and expressed mostly immunoglobulin (Ig) MK, CD10, CD19, CD20, CD22, and CD38.
|
8209868 |
1994 |
Burkitt Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using anti-human B cell monoclonal antibodies prepared against B1 (CD20), B2 (CD21), B4 (CD19), and BB-1 (B lymphoblast antigen-1), we compared the expression of B cell differentiation antigens on a Jijoye-P3HR-1 cell line family of Burkitt's lymphomas.
|
2850450 |
1988 |